Opinion
Video
Clinical Experience With Initiating Adalimumab Biosimilars
Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars.
This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
The discussion revolves around experiences initiating patients on biosimilars. For bionaive patients, the process is generally smooth, often involving in-office injections to familiarize patients with administration techniques. However, stable patients may express hesitancy, primarily due to concerns about cost. Educating patients about copay programs and assisting them in enrolling in financial assistance programs can alleviate these concerns.
Transitioning patients to biosimilars can be challenging, especially concerning logistical issues like insurance coverage and medication delivery. Clear communication and proactive enrollment in support programs are essential to prevent treatment interruptions.
Patient education is crucial to address concerns and dispel misconceptions, particularly regarding the nocebo effect. Consistency in messaging across healthcare staff is emphasized to build patient confidence.
Practical strategies for patient education include using lay language, keeping explanations concise, and repeating key information to reinforce understanding. Healthcare professionals also play a vital role in promoting biosimilar use and improving patient care through ongoing education and support.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
